Commentary “Financial discipline has been one of the hallmarks of the Company, and for the last 19 years Darren has provided stability, and strong leadership,” CLINUVEL’s CEO, Dr Philippe Wolgen said. “He has been with CLINUVEL from its turnaround in 2005 to help it become one of the few profitable pharmaceuticals launching new molecular entities in the Southern hemisphere. “Darren leaves the Company in a superior financial position. On behalf of the Board and staff, I wish him well in his future endeavours as he hands over to Peter.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)